cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized powder form |
| Solubility class | Freely soluble in water | Also dissolves in polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or lower | Desiccated and protected from light |
| Typical analytical method | Reversed-phase HPLC with UV detection | Purity reported by area normalization |
| Common synonyms | PT-141; bremelanotide | Research code and assigned generic name |
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
=== Synthesis === Trimebutine can be synthesised from 1-phenylpropan-1-one (1). Firstly, it is converted to the corresponding oxirane through trimethylsulfoxonium idoide with sodium hydride in DMSO and THF, yielding 2-ethyl-2-phenyl-oxirane (2). Next, 2 undergoes ring-opening with dimethylaluminium N,N-dimethylamide in diethyl ether, yielding 2-(dimethylamino)-2-phenyl-butan-1-ol (4) and 2-phenylbutanal (3) as a byproduct. Then, 4 reacts with 3,4,5-trimethoxybenzoyl chloride (5) in triethylamine and THF, which is catalysed by 4-dimethylaminopyrridine (DMAP), yielding trimebutine.
=== Cuban oil reserves === On 25 April 2026, Miguel Díaz-Canel celebrated this week as a historic milestone the fact that Cuban national crude can be refined, when in reality the Cabaiguán refinery has been processing that same oil since 2010, as acknowledged by the deputy director of CUPET during the April session of the National Council of Innovation (CNI). The announcement from the Cuban government revolves around a thermal conversion technology developed by the Oil Research Center (Ceinpet), affiliated with the Union Cuba Petróleo (CUPET), to process the heavy crude from the northern oil belt, characterized by its high density, viscosity, and sulfur content.
=== Abiogenic petroleum === An alternative mechanism to the one described above was proposed by Russian scientists in the mid-1850s, the hypothesis of abiogenic petroleum origin (petroleum formed by inorganic means), but this is contradicted by geological and geochemical evidence. Abiogenic sources of oil have been found but never in commercially profitable amounts. "The controversy isn't over whether abiogenic oil reserves exist," said Larry Nation of the American Association of Petroleum Geologists. "The controversy is over how much they contribute to Earth's overall reserves and how much time and effort geologists should devote to seeking them out."
=== British Empire Medal (BEM) === Civil Division Dewitt Carey, . For services to the community. The Reverend Carlton Alexander Farquharson, . For services to the Island of Inagua. Rosie Grant. For services to the community. Eleazor James Johnson. For services to sailing. Captain Hezron Lenox Moxey. For services to sailing. Theophilus Neely, . For services to the community of South Andros. Lindsay Williamson. For services to the community. Mildred Williamson. For services to the community. Otis Young, . For services to South Eleurhera.
=== Pregnancy and breastfeeding === Spironolactone can cross the placenta. It has been found in the breast milk of lactating mothers, but only very small amounts of spironolactone and its metabolite canrenone enter breast milk, and the amount received by an infant during breastfeeding (<0.5% of the mother's dose) is considered to be insignificant. A study found that spironolactone was not associated with teratogenicity in the offspring of rats. Because it is an antiandrogen, however, spironolactone could theoretically have the potential to cause feminization of male fetuses at sufficient doses. In accordance, a subsequent study found that partial feminization of the genitalia occurred in the male offspring of rats that received doses of spironolactone that were five times higher than those normally used in humans (200 mg/kg per day). Another study found permanent, dose-related reproductive tract abnormalities rat offspring of both sexes at lower doses (50 to 100 mg/kg per day). In practice however, although experience is limited, spironolactone has never been reported to cause observable feminization or any other congenital defects in humans. Among 31 human newborns exposed to spironolactone in the first trimester, no signs of any specific birth defects were seen. A case report described a woman who was prescribed spironolactone during pregnancy with triplets and delivered all three (one boy and two girls) healthy; no observable feminization occurred in the boy.
Sources: en.wikipedia.org
== Terminology == The term accepted point mutation was initially used to describe the mutation phenomenon. However, the acronym PAM was preferred over APM due to readability, and so the term point accepted mutation is used more regularly. Because the value
== Status == In the context of perpetual motion machines such as the Orbo, Professor Eric Ash has argued at the BBC: "Denying [conservation of energy] would undermine not just little bits of science - the whole edifice would be no more. All of the technology on which we built the modern world would lie in ruins". It is because of conservation of energy that "we know - without having to examine details of a particular device - that Orbo cannot work." Energy conservation has been a foundational physical principle for about two hundred years. From the point of view of modern general relativity, the lab environment can be well approximated by Minkowski spacetime, where energy is exactly conserved. The entire Earth can be well approximated by the Schwarzschild metric, where again energy is exactly conserved. Given all the experimental evidence, any new theory (such as quantum gravity), in order to be successful, will have to explain why energy has appeared to always be exactly conserved in terrestrial experiments. In some speculative theories, corrections to quantum mechanics are too small to be detected at anywhere near the current TeV level accessible through particle accelerators. Doubly special relativity models may argue for a breakdown in energy-momentum conservation for sufficiently energetic particles; such models are constrained by observations that cosmic rays appear to travel for billions of years without displaying anomalous non-conservation behavior.
The issue of whether birds should continue to be actively collected for research has been the subject of some debate among ornithologists (examples of this can be found in the lively exchanges between Remsen and Bekoff & Elzanowski, between Vuilleumier and Donegan, and between Dubois & Nemesio and Donegan). Those opposed to collecting believe that much of current collecting is unnecessary, arguably motivated by the personal field scores of individuals or by competition between museums, rather than the result of a strict scientific rationale; that collecting, in extreme cases of species on the verge of extinction, can pose a threat to bird populations; and that in many cases in which the necessity of specimens is claimed, new technology such as digital photography and blood sample analysis of mist-netted individuals could instead be used. Finally, at a time of rampant deforestation and species extinctions, scientists and conservationists should take the lead in providing an example to local people not to kill or hunt birds. Where other techniques not involving killing of a bird are feasible, to take a specimen is viewed by some as simply unethical. Proponents of collecting counter-argue that compared to the many millions of birds killed each year by habitat destruction, domestic cats, window strikes, and tower kills, scientists collect only a few thousand birds per year worldwide and populations will quickly recover from an episode of collecting as long as their habitat remains.
A type of research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis, or treatment of a disease. Also called a clinical trial. (NCI) A clinical trial is a research study to answer specific questions about vaccines or new therapies or new ways of using known treatments. Clinical trials (also called medical research and research studies) are used to determine whether new drugs or treatments are both safe and effective. Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people. Trials are in four phases: Phase I tests a new drug or treatment in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people; and Phase IV takes place after the drug or treatment has been licensed and marketed. (NLM) Any investigation in human subjects intended to discover or verify the clinical, pharmacological, and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to study absorption, distribution, metabolism, and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy. The terms clinical trial and clinical study are synonymous. (ICH E6) Clinical Trial/Study Report
In 2020, world production of soybeans was over 353 million tonnes, led by Brazil and the United States combined with 66% of the total (table). Production has dramatically increased across the globe since the 1960s, but particularly in South America after a cultivar that grew well in low latitudes was developed in the 1980s. The rapid growth of the industry has been primarily fueled by large increases in worldwide demand for meat products, particularly in developing countries like China, which alone accounts for more than 60% of imports. Soy is a staple crop; global soy production accounts for four times more legume production than all other legumes combined.
Sources: en.wikipedia.org
anode 1. An electrode through which the conventional electric current (the flow of positive charges) enters into a polarized electrical circuit. 2. The wire or plate of an electrochemical cell having an excess positive charge. Negatively charged anions always move toward the anode. Contrast cathode.
Northern Ireland Samuel Paul Henderson, lately Detective Constable, Police Service of Northern Ireland. Nicola Marie Marshall, Detective Superintendent, Police Service of Northern Ireland. Kieran Quinn, Inspector, Police Service of Northern Ireland.
Continuous-wave lasers however are often preferred to pulsed lasers due to the latter's relatively low duty cycle since they can only produce photo ions during the brief later pulses, and the difficulty in reproducing results due to pulse-to-pulse jitters, laser beam drifting, and wavelength variations. Moderate laser powers, if high enough to affect the desired transition states, can be used since the non-resonant photoionization cross section is low which implies a negligible ionization efficiency of unwanted atoms. The influence of the laser matrix to be used for the sample can also be reduced by separating evaporation and ionization processes both in time and in space. Another factor that could affect the efficiency and selectivity of the ionization process is the presence of contaminants caused by surface or impact ionization. This can be reduced up to appreciable orders of magnitude by using mass analysis so that isotopic compositions of the desired element are determined. Most of the elements of the Periodic Table can be ionized by one of the several excitation schemes available. The suitable excitation scheme depends on certain factors including the level scheme of the element's atom, its ionization energy, required selectivity and sensitivity, likely interference, and the wavelengths and power levels of the available laser systems. Most excitation schemes vary in the last step, the ionization step. This is due to the low cross-section for non-resonant photo-ionization produced by the laser.
=== Pharmacokinetics === Information about pharmacokinetics and pharmacodynamics of DNP in humans is limited. DNP is metabolized via nitro reduction. Its major metabolites are 2-amino-4-nitrophenol and 4-amino-2-nitrophenol. In overdoses, symptom onset can be as soon as 3 hours and the average time to death was 14 hours.
A Cochrane Review on treatments for acute CRAO included one randomized clinical trial involving pentoxifylline, which showed that pentoxifylline use (three 600 mg tablets daily) was associated with improved retinal perfusion, but it was unclear if significant improvements in visual acuity were also observed. Similar findings have been shown using Doppler OCT imaging in patients with NAION, though a study in India reported visual improvement compared to placebo in patients with optic neuropathy. Of note, TNF may be important in the immune response to certain nematode parasitic infections, and so pentoxifylline should be used with caution for those living in areas of parasite infestation; however, it is probably safe to use in otherwise healthy individuals living in urban, temperate environments. Overall, routine use of pentoxifylline in ischemic optic neuropathies was not supported given limited evidence, but the absence of major adverse effects and the absence of other proven therapies suggest a possible therapeutic role for pentoxifylline.
Sources: en.wikipedia.org
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.
Retention time supports consistency but does not establish structure by itself. A different compound can elute at a similar time under one set of conditions. Mass spectrometry or comparison with a verified standard is normally required alongside the chromatographic result.
The lactam bridge constrains the peptide backbone and limits attack by some exopeptidases. It does not protect against hydrolysis of amide bonds inside the ring or against oxidative modification of susceptible residues. Stability therefore still depends heavily on storage conditions.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.